NewsSource: EClinCloud

Copyright and Licensing Considerations When Using Existing COA Scales in Clinical Trials

7 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: eClinCloud.


Click the "blue text" above to follow us
Article illustration


On June 16, 2020, the U.S. Food and Drug Administration (FDA) issued "Patient-Focused Drug Development: Collecting Comprehensive and Representative Input" Guidance for Industry, aimed at facilitating the systematic collection of reliable information from patients and caregivers.

In recent years, the entire healthcare industry has been shifting toward a "patient-centric" value system. To better serve patients, life sciences companies have invested substantial effort in listening to patient perspectives before, during, and after clinical trials. Clinical outcome assessment (COA) is an indispensable tool for collecting and analyzing real-world data (RWD) during clinical trials to improve drug therapy.
Article illustration
Clinical Outcome Assessment (COA)
Clinical Outcome Assessments (COA)

The FDA defines a COA as a tool that describes or reflects how a patient feels, functions, or survives in a clinical trial, and can be a clinical outcome assessment reported by a clinician, patient, or non-clinician observer, or a performance-based assessment.


COAs include the following 4 types, among which PROs are the most widely used.

  • Patient-Reported Outcome

    Patient-Reported Outcome (PRO)

  • Clinician-Reported Outcome

    Clinician-Reported Outcome (ClinRO)

  • Observer-Reported Outcome

    Observer-Reported Outcome (ObsRO)

  • Performance Outcome

    Performance Outcome (PerfO)


PRO

A subjective response coming directly from the patient about their health condition and health-related aspects, which does not include evaluation of the patient's subjective response by a clinician or anyone else.


A PRO can be measured by self-report or interview, provided that the interviewer only records the patient's responses. Symptoms or other unobservable concepts known only to the patient (for example, pain severity or nausea) can only be measured by PRO assessments. A PRO can also assess the patient's perspective on functioning or activities (which may also be observable by others).



ClinRO

An assessment of a report of the patient's health condition performed by a healthcare professional. Most ClinRO assessments involve clinical judgment or interpretation, including observable signs, behaviors, or other disease-related phenomena. ClinRO assessments cannot directly assess symptoms known only to the patient (for example, pain intensity).



ObsRO

An assessment of a report of the patient's health condition performed by someone other than the patient or a healthcare professional, covering signs, events, or behaviors related to the patient's health condition. Typically, an ObsRO is reported by a parent, caregiver, or someone who observes the patient in daily life, and ObsROs are especially useful for patients who cannot self-report (for example, infants or individuals with cognitive impairment). ObsRO assessments do not include clinical judgment or interpretation.



PerfO

An assessment of a standardized task performed by the patient. The standardized task may be administered and evaluated by trained personnel, or completed independently by the patient. PerfOs require the patient's cooperation; these assessments include gait speed tests (for example, the Timed 25-Foot Walk test), memory tests (for example, a word recall test), or other cognitive tests (for example, the Digit Symbol Substitution Test).


Accurate clinical outcome assessment (COA) is key to the success of a clinical trial. To obtain valuable information from clinical trial patients, using an appropriate COA measurement tool is a prerequisite for obtaining accurate and reliable results. COA measurement is typically conducted using validated scales.


Article illustration


Scales are a measurement and assessment tool commonly used in clinical practice

and an essential instrument for assessing disease severity and supporting objective diagnosis and treatment.

Compared with other examination methods,

scales are simpler and more accurate to use,

and have therefore become

an important standard for measuring treatment effects in evidence-based medicine research.

  

01
What is a scale?

A scale is a measurement tool jointly developed by multiple teams or disciplines (such as clinical medicine and psychology) for a specific research purpose to quantify impressions obtained through observation. It is typically administered as a standardized questionnaire and can be used in the general healthy population or in populations with a specific disease.

 

As a major component of clinical outcome assessment (COA), scales are undoubtedly also an essential one. Information collected through scales provides insights into specific populations, such as symptoms, overall health status, and the impact of disease and treatment on patients' quality of life.

 

02
Why are scales important?

Today, scales have become an important part of routine clinical work, helping clinicians quickly identify the root cause of a problem.

 

Even laboratory tests with high sensitivity and specificity cannot replace neuropsychological scale assessments, which quantify cognitive function and assist with localization and qualitative diagnosis. Neuropsychological assessment helps guide diagnostic and treatment plans, evaluate treatment efficacy, and predict disease progression, and has become an important tool in clinical practice and clinical research across departments such as neurology, neurosurgery, psychiatry, geriatrics, and rehabilitation and sports medicine.

 

In addition, scales help physicians conduct effective patient management and follow-up.

 

03
What should you watch out for when using existing scales?

While scales are widely used and very important in clinical practice, using existing scales requires attention to copyright and licensing. With a wide variety of scales, varying degrees of validation, and uneven quality, selecting the appropriate version can also be difficult.

 

04
What are the risks of using an unlicensed scale or using a scale improperly?
  • The copyright holder refuses authorization

  • Higher, punitive licensing fees may be charged

  • Delays in obtaining copyright clearance cause project delays

  • Unprofessional translation may also lead to:

         - Disapproval by the ethics committee

         - Revocation of the license by the copyright holder

         - Rejection letter from regulatory authorities

         - Re-commissioning of the translation

  

05
What is the process for obtaining scale licensing and Chinese localization?
  • Identification / Due Diligence (1–2 weeks)

    - Select the appropriate scale version and required number of copies, and confirm available scale languages

    - Identify the copyright holder and costs associated with purchasing the license

 

  • Rights / Licensing (1–2 weeks)

     - Contact the copyright holder to obtain authorization to use the scale

     - Receive the original English version of the scale

 

  • Translation / Validation (6–8 weeks)

     - Translate the scale in accordance with cross-cultural adaptation guidelines, including translation, reconciliation, back-translation, and cultural adaptation

     - Deliver the final translated scale version and corresponding Certificates of Translation (COTs) to the sponsor

 

  • Execution

    - Scale quality control

    - Distribution of paper scales (if needed)


06
When should you start preparing scales?

Working backward from copyright-holder outreach through scale translation and validation, it is best to allow at least 3 months prior to the IRB submission date.

 

 

For all of these processes and challenges,

EClinCloud

can help you resolve them.

 

Our Advantages

A professional medical team interprets the protocol and determines the exact scale version;


Well-established collaborative relationships with multiple scale authors or copyright holders, with fast response times;


The service team has extensive eCOA implementation experience, with large-scale international project experience across every stage, including copyright management, scale migration, device rental and maintenance, and data analysis and reporting;


eCOA systems and processes are recognized by regulatory authorities such as the FDA, holding more than 50% of the global market share;


With a local service team in place, client communication is more convenient;


Collaborative relationships with local neurology experts (KOLs) to provide rater training and certification services.


EClinCloud

EClinCloud aims to build a leading clinical research cloud platform. Guided by the mission of "bringing effective treatments to patients through technological innovation," it is a healthcare and life sciences technology company based in China and serving the world.
EClinCloud's clinical research cloud platform is an independently developed, end-to-end, seamlessly integrated all-in-one platform, including electronic informed consent (eConsent), electronic data capture (EDC), randomization and trial supply management (RTSM), electronic clinical outcome assessment (eCOA), clinical trial management system (CTMS), electronic trial master file (eTMF), risk-based monitoring (RBM), and virtual trials (Virtual Trial). Through EClinCloud's specialized solutions, pharmaceutical companies, medical device companies, and research institutions can accelerate new drug R&D, reduce clinical research costs, and lower clinical research risks.
Article illustration

Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.